Affiliated Cancer Hospital & Institute Of Guangzhou Medical University

This study tests a new combination treatment for women whose ovarian cancer has returned after standard therapy. About 40 participants will receive QL1706 (a dual-target immunotherapy) together with chemotherapy and anlotinib (a pill that blocks blood vessel growth). The goal is …

This study tests whether adding a new immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with locally advanced cervical cancer. About 50 women with stage IB3 or IIA2 cervical cancer who have not had prior treatment will receive the…